CRISPR/Cas9-mediated genetic correction reverses spinocerebellar ataxia 3 disease-associated phenotypes in differentiated cerebellar neurons

Abstract

The neurodegenerative disease spinocerebellar ataxia type 3 (SCA3; also called Machado-Joseph disease, MJD) is a trinucleotide repeat disorder caused by expansion of the CAG repeats in the ATXN3 gene. Here, we applied a CRISPR/Cas9-mediated approach using homologous recombination to achieve a one-step genetic correction in SCA3-specific induced pluripotent stem cells (iPSCs). The genetic correction reversed disease-associated phenotypes during cerebellar region-specific differentiation. In addition, we observed spontaneous ataxin-3 aggregates specifically in mature cerebellar neurons differentiated from SCA3 iPSCs rather than in SCA3 pan-neurons, SCA3 iPSCs or neural stem cells, suggesting that SCA3 iPSC-derived disease-specific and region-specific cerebellar neurons can provide unique cellular models for studying SCA3 pathogenesis in vitro. Importantly, the genetically corrected cerebellar neurons did not display typical SCA3 aggregates, suggesting that genetic correction can subsequently reverse SCA3 disease progression. Our strategy can be applied to other trinucleotide repeat disorders to facilitate disease modeling, mechanistic studies and drug discovery.

Keywords

genetic correction / spinocerebellar ataxia 3 / iPSC / CRISPR/Cas9 / cell differentiation

References

[1] Evers MM, Toonen LJ, van Roon-Mom WM. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol Neurobiol 2014;49:1513–31.

[2] Schols L, Bauer P, Schmidt T, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3:291–304.

[3] Saute JAM, Jardim LB. Machado Joseph disease: clinical and genetic aspects, and current treatment. Expert Opin Orphan Drugs 2015;3:517–35.

[4] Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221–8.

[5] Costa Mdo C, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol 2012;97:239–57.

[6] Matos CA, de Macedo-Ribeiro S, Carvalho AL. Polyglutamine diseases: the special case of ataxin-3 and Machado–Joseph disease. Prog Neurobiol 2011;95:26–48.

[7] Berke SJ, Schmied FA, Brunt ER, et al. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 2004;89:908–18.

[8] Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011;480:543–6.

[9] Auer TO, Duroure K, De Cian A, et al. Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res 2014;24:142–53.

[10] Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014;159:440–55.

[11] Young CS, Hicks MR, Ermolova NV, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 2016;18:533–40.

[12] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.

[13] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual- RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337: 816–21.

[14] Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281–308.

[15] Zhang F, Song G, Tian Y. Anti-CRISPRs: the natural inhibitors for CRISPR-Cas systems. Anim Model Exp Med 2019;2:69–75.

[16] Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 2016;539:384–9.

[17] Park CY, Kim DH, Son JS, et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia a patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell 2015b;17:213–20.

[18] Wu Y, Liang D, Wang Y, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013;13:659–62.

[19] Muffat J, Li Y, Jaenisch R. CNS disease models with human pluripotent stem cells in the CRISPR age. Curr Opin Cell Biol. 2016;43:96–103.

[20] Xue Y, Cai X, Wang L, et al. Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells. PLoS One 2013;8:e70573.

[21] Muguruma K, Nishiyama A, Kawakami H, et al. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep 2015;10:537–50.

[22] Koch P, Opitz T, Steinbeck JA, et al. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc Natl Acad Sci USA 2009;106:3225–30.

[23] Tailor J, Kittappa R, Leto K, et al. Stem cells expanded from the human embryonic hindbrain stably retain regional specification and high neurogenic potency. J Neurosci 2013;33:12407–22.

[24] Bichelmeier U, Schmidt T, Hubener J, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 2007;27:7418–28.

[25] Paulson HL, Perez MK, Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333–44.

[26] Yan Y, Shin S, Jha BS, et al. Efficient and rapid derivation of primitive neural stem cells and generation of brain subtype neurons from human pluripotent stem cells. Stem Cells Transl Med 2013;2:862–70.

[27] Hubener J, Weber JJ, Richter C, et al. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hum Mol Genet 2013;22:508–18.

[28] Liman J, Deeg S, Voigt A, et al. CDK5 protects from caspase- induced Ataxin-3 cleavage and neurodegeneration. J Neurochem 2014;129:1013–23.

[29] Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011;475:324–32.

[30] Seidel K, Meister M, Dugbartey GJ, et al. Cellular protein quality control and the evolution of aggregates in spinocerebellar ataxia type 3 (SCA3). Neuropathol Appl Neurobiol 2012;38:548–58.

[31] An MC, O’Brien RN, Zhang N, et al. Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR/Cas9 system. PLoS Curr 2014;6:ecurrents.hd.0242d2e7ad72225efa72f6964589369a.

[32] An MC, Zhang N, Scott G, et al. Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253–63.

[33] Park CY, Halevy T, Lee DR, et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep 2015a;13:234–41.

[34] He L, Wang S, Peng L, et al. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patientderived induced pluripotent stem cells. Transl Psychiatry 2021;11:479.

[35] Marthaler AG, Tubsuwan A, Schmid B, et al. Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H266. Stem Cell Res 2016;16:202–5.

[36] Xu XH, Tay YL, Sim B, et al. Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in huntington disease patient-derived induced pluripotent stem cells. Stem Cell Rep 2017;8:619–33.

[37] Ouyang S, Xie Y, Xiong Z, et al. CRISPR/Cas9-targeted deletion of polyglutamine in spinocerebellar ataxia type 3-derived induced pluripotent stem cells. Stem Cells Dev 2018;27:756–70.

[38] Takahashi T, Kikuchi S, Katada S, et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet 2008;17:345–56.

[39] Chou AH, Yeh TH, Ouyang P, et al. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 2008;31:89–101.

[40] Yu YC, Kuo CL, Cheng WL, et al. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J Neurosci Res 2009;87:1884–91.

[41] Liu H, Li X, Ning G, et al. The Machado-Joseph disease deubiquitinase ataxin-3 regulates the stability and apoptotic function of p53. PLoS Biol 2016;14:e2000733.

[42] Anzalone AV, Gao XD, Podracky CJ, et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol 2022;40:731–40.

[43] Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019;576:149–57.

[44] Shakkottai VG, do Carmo Costa M, Dell’Orco JM, et al. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci 2011;31:13002–14.

[45] Song G, Zhang F, Tian C, et al. Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing. Nucleic Acids Res 2022;50:2836–53.

[46] Song G, Zhang F, Zhang X, et al. AcrIIA5 inhibits a broad range of Cas9 orthologs by preventing DNA target cleavage. Cell Rep 2019;29:2579–89.

[47] Chang CW, Lai YS, Westin E, et al. Modeling human severe combined immunodeficiency and correction by CRISPR/Cas9-enhanced gene targeting. Cell Rep 2015;12:1668–77.

[48] Firth AL, Menon T, Parker GS, et al. Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs. Cell Rep 2015;12:1385–90.

[49] Zhu X, Xu Y, Yu S, et al. An efficient genotyping method for genome-modified animals and human cells generated with CRISPR/Cas9 system. Sci Rep 2014;4:6420.

[50] Hazeki N, Tukamoto T, Goto J, et al. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. Biochem Biophys Res 2000;277:386–93.

RIGHTS & PERMISSIONS

2022 The Author(s) 2022